Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sales & Earnings China Cancer

AstraZeneca CEO: Explosive Q1 China Growth Will Ease In 2H, Then Reignite

Executive Summary

AstraZeneca generated 28% sales growth in China during the first quarter - but the UK group's CEO said that stellar performance will decline somewhat in the second half.

You may also be interested in...



AstraZeneca Q2 Preview: Cancer Drug Trio To Keep Growing

Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.

Q1 Drug Sales, Pipeline, 2019 Catalysts Top Themes For AstraZeneca Update

Q1 Earnings Preview: When AstraZeneca reports first-quarter results on April 26 investor focus will be on new product sales growth, pipeline catalysts and clues on possible fresh divestment and licensing deals.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Table

View full table

Topics

Related Companies

Tags:
Sales & Earnings China Cancer
Latest Headlines

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Falling Sales Force New Priorities At Roche

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

See All
UsernamePublicRestriction

Register

SC125133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By